Hospital
Wheeling Hospital INC
Wheeling Hospital INC was paid $40.14M by Medicaid between Jan 2018 and Dec 2024, across 462 billing codes. Its largest line is 99284, emergency room visit (serious) — 7.3% of everything it billed.
33Billing provider infoWHEELING HOSPITAL INC
WHEELING, WV 26003
WHEELING, WV 26003
33aNPI1104821305assigned 06/15/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$40.14M
24GClaims1,151,306
24DCodes billed462
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in West Virginia
Rank by total paid#9 of 26
Median peer was paid$18.33M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 144,841 | $10.74M | |
| 2019 | 121,922 | $6.78M | |
| 2020 | 199,741 | $10.08M | |
| 2021 | 173,762 | $3.72M | |
| 2022 | 94,860 | $1.67M | |
| 2023 | 244,183 | $3.88M | |
| 2024incomplete | 171,997 | $3.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.3% | 23,087 | 19,418 | $2.92M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.6% | 68,903 | 51,625 | $2.23M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.7% | 38,935 | 32,741 | $1.47M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.6% | 6,608 | 5,234 | $1.43M |
| 80053 | Comprehensive metabolic panel | 3.1% | 56,391 | 44,143 | $1.26M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.0% | 14,617 | 13,109 | $1.19M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 4,036 | 3,282 | $1.08M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.5% | 67,088 | 51,247 | $1.00M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 12,084 | 8,742 | $896K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.9% | 12,808 | 4,561 | $744K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 5,260 | 4,333 | $663K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 2,478 | 2,030 | $607K |
450 more codes
| 36415 | Collection of venous blood by venipuncture | 1.5% | 61,215 | $585K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 4,685 | $575K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 9,941 | $566K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 6,063 | $494K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.1% | 11,584 | $458K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 18,238 | $452K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 5,588 | $446K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 6,196 | $443K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 20,800 | $415K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,193 | $392K |
| G0378 | Hospital observation service, per hour | <1% | 4,915 | $378K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,696 | $367K |
| 80061 | Lipid panel | <1% | 13,312 | $343K |
| 81001 | <1% | 23,062 | $338K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,926 | $334K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,452 | $329K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 10,707 | $328K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 13,545 | $324K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,378 | $321K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,247 | $318K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 9,262 | $308K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,455 | $305K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 5,796 | $271K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 6,303 | $261K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,924 | $252K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,893 | $251K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,901 | $250K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,964 | $242K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,482 | $241K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 5,432 | $233K |
| 84484 | <1% | 10,916 | $228K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,576 | $222K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,501 | $222K |
| 96367 | <1% | 3,936 | $220K | |
| 59025 | Fetal non-stress test | <1% | 3,286 | $218K |
| J2704 | Injection, propofol, 10 mg | <1% | 8,412 | $215K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 15,124 | $215K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,433 | $210K |
| 87088 | <1% | 7,333 | $201K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,010 | $199K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,964 | $195K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 691 | $195K |
| 85610 | <1% | 9,329 | $195K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,080 | $186K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,063 | $182K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,040 | $182K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,770 | $179K |
| 85730 | <1% | 5,211 | $174K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,821 | $170K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,423 | $168K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,105 | $165K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 8,690 | $165K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 744 | $163K |
| 83690 | <1% | 8,622 | $162K | |
| 81025 | <1% | 4,585 | $162K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,841 | $157K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,452 | $151K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 532 | $148K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,964 | $141K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,406 | $141K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 744 | $139K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,759 | $135K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,269 | $134K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 2,963 | $129K |
| 80074 | <1% | 1,500 | $124K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,609 | $123K |
| 82962 | <1% | 6,425 | $123K | |
| 96376 | <1% | 3,786 | $123K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,633 | $122K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,691 | $118K |
| 97161 | <1% | 2,787 | $112K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,170 | $107K |
| 84702 | <1% | 3,008 | $105K | |
| 83735 | <1% | 11,341 | $103K | |
| 82150 | <1% | 3,079 | $100K | |
| 92557 | <1% | 2,104 | $95K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,956 | $95K |
| 87040 | <1% | 4,105 | $95K | |
| 84439 | <1% | 4,255 | $93K | |
| 84703 | <1% | 3,743 | $86K | |
| 73564 | <1% | 1,880 | $86K | |
| 82550 | <1% | 2,074 | $82K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 598 | $82K |
| 74018 | <1% | 1,795 | $81K | |
| 82553 | <1% | 1,043 | $80K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,698 | $79K |
| 86850 | <1% | 4,901 | $76K | |
| 87071 | <1% | 1,347 | $73K | |
| 97010 | <1% | 3,721 | $71K | |
| 73630 | <1% | 2,092 | $71K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,155 | $69K |
| 86703 | <1% | 1,257 | $69K | |
| 92567 | <1% | 3,706 | $68K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,948 | $68K |
| 86900 | <1% | 5,348 | $67K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,344 | $66K |
| 82565 | <1% | 2,209 | $65K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 6,200 | $65K |
| 76642 | <1% | 897 | $65K | |
| 72110 | <1% | 1,147 | $65K | |
| 83880 | <1% | 2,569 | $64K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,864 | $63K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,722 | $61K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,003 | $61K |
| 92551 | <1% | 6,037 | $60K | |
| 93000 | <1% | 6,415 | $60K | |
| 86803 | <1% | 2,823 | $60K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 275 | $59K |
| 85027 | <1% | 8,518 | $58K | |
| 86901 | <1% | 2,788 | $58K | |
| A4649 | Surgical supply; miscellaneous | <1% | 241 | $57K |
| 73610 | <1% | 1,477 | $57K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,867 | $56K |
| 87070 | <1% | 2,836 | $56K | |
| 87522 | Neg quan hep c or qual rna | <1% | 736 | $55K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,502 | $55K |
| 82607 | <1% | 2,982 | $55K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 921 | $53K |
| 93925 | <1% | 253 | $52K | |
| 81003 | <1% | 5,076 | $52K | |
| 87186 | <1% | 3,308 | $51K | |
| 93880 | <1% | 727 | $50K | |
| 87634 | <1% | 753 | $49K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 182 | $48K |
| 87077 | <1% | 1,876 | $47K | |
| 86592 | <1% | 2,005 | $47K | |
| 71250 | <1% | 579 | $46K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 421 | $45K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 998 | $45K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,560 | $44K |
| 77065 | Tomosynthesis, mammo | <1% | 687 | $44K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 761 | $43K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,360 | $43K |
| 90715 | <1% | 1,627 | $41K | |
| 97035 | <1% | 670 | $40K | |
| 83605 | <1% | 3,933 | $40K | |
| 82746 | <1% | 1,633 | $40K | |
| 85652 | <1% | 2,878 | $39K | |
| 73130 | <1% | 909 | $39K | |
| 20610 | <1% | 664 | $38K | |
| 82043 | <1% | 2,830 | $37K | |
| 94760 | <1% | 1,277 | $37K | |
| 86762 | <1% | 1,477 | $37K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,153 | $36K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 884 | $36K |
| 73030 | <1% | 1,434 | $36K | |
| 86140 | <1% | 2,530 | $36K | |
| 87340 | <1% | 1,925 | $36K | |
| 80050 | General health panel | <1% | 1,190 | $35K |
| 88342 | <1% | 1,323 | $35K | |
| 93017 | <1% | 684 | $35K | |
| J3490 | Unclassified drugs | <1% | 2,797 | $34K |
| 87430 | <1% | 1,064 | $34K | |
| 93971 | <1% | 475 | $34K | |
| 70486 | <1% | 224 | $34K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 3,273 | $34K |
| 95886 | <1% | 456 | $34K | |
| 93015 | <1% | 880 | $33K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 40 | $33K |
| 83615 | <1% | 2,033 | $32K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 6,921 | $32K |
| 97803 | <1% | 964 | $31K | |
| 73110 | <1% | 754 | $30K | |
| 93970 | <1% | 347 | $29K | |
| 88304 | <1% | 616 | $29K | |
| 97165 | <1% | 1,062 | $29K | |
| 84146 | <1% | 605 | $28K | |
| C1769 | Guide wire | <1% | 532 | $28K |
| 84550 | <1% | 1,975 | $28K | |
| 94762 | <1% | 314 | $28K | |
| 82728 | <1% | 2,103 | $28K | |
| 82105 | <1% | 921 | $28K | |
| 73502 | <1% | 846 | $27K | |
| 36591 | <1% | 1,546 | $27K | |
| 85379 | <1% | 1,329 | $27K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,205 | $27K |
| 90670 | <1% | 2,558 | $26K | |
| 80076 | <1% | 1,139 | $26K | |
| 82570 | <1% | 1,992 | $26K | |
| 82950 | <1% | 1,341 | $26K | |
| 84153 | <1% | 957 | $26K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,293 | $25K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 2,678 | $25K |
| 96150 | <1% | 328 | $25K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 535 | $25K |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 212 | $24K |
| 87205 | <1% | 1,707 | $24K | |
| 83540 | <1% | 2,445 | $24K | |
| 96415 | <1% | 176 | $23K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 427 | $23K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 70 | $22K |
| 76536 | <1% | 185 | $22K | |
| J1741 | Injection, ibuprofen, 100 mg | <1% | 319 | $22K |
| 95911 | <1% | 13 | $22K | |
| 84156 | <1% | 1,009 | $21K | |
| 76801 | <1% | 286 | $20K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 101 | $18K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,790 | $18K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,253 | $18K |
| 90686 | <1% | 3,374 | $17K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 74 | $17K |
| 77066 | Tomosynthesis, mammo | <1% | 172 | $17K |
| 77336 | <1% | 203 | $17K | |
| 87400 | <1% | 919 | $16K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,698 | $16K |
| 83001 | <1% | 336 | $16K | |
| 84460 | <1% | 1,271 | $15K | |
| 90837 | Psychotherapy session, about an hour | <1% | 181 | $15K |
| 83550 | <1% | 827 | $15K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 343 | $15K |
| 86038 | <1% | 591 | $15K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 572 | $15K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 195 | $13K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,046 | $13K |
| 85018 | <1% | 1,585 | $13K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 290 | $12K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 335 | $12K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 361 | $12K |
| 00731 | <1% | 313 | $12K | |
| 87081 | <1% | 1,421 | $12K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 13 | $12K |
| 84450 | <1% | 1,008 | $11K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 688 | $11K |
| 83655 | <1% | 760 | $11K | |
| 94729 | <1% | 488 | $11K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 139 | $11K |
| 92523 | <1% | 126 | $11K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $10K |
| 97116 | <1% | 962 | $10K | |
| 84403 | <1% | 411 | $10K | |
| C1819 | Surgical tissue localization and excision device (implantable) | <1% | 56 | $10K |
| 76770 | <1% | 194 | $9K | |
| 93975 | <1% | 88 | $9K | |
| 86618 | <1% | 542 | $9K | |
| 82805 | <1% | 144 | $9K | |
| 94726 | <1% | 376 | $8K | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 281 | $8K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 145 | $8K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 627 | $8K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 116 | $8K |
| 11721 | <1% | 843 | $8K | |
| 95811 | <1% | 28 | $8K | |
| 84481 | <1% | 629 | $7K | |
| 73560 | <1% | 400 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 481 | $7K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 172 | $7K |
| 97014 | <1% | 155 | $7K | |
| 96156 | <1% | 248 | $7K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 87 | $7K |
| 83002 | <1% | 149 | $6K | |
| 82977 | <1% | 361 | $6K | |
| 76775 | <1% | 58 | $6K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 974 | $6K |
| 73590 | <1% | 220 | $6K | |
| 72100 | <1% | 141 | $6K | |
| 87481 | <1% | 170 | $6K | |
| 96127 | <1% | 196 | $6K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 93 | $5K |
| 80143 | <1% | 628 | $5K | |
| 90648 | <1% | 3,102 | $5K | |
| 80179 | <1% | 626 | $5K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 284 | $5K |
| 72131 | <1% | 189 | $5K | |
| 84100 | <1% | 1,523 | $5K | |
| 85014 | <1% | 236 | $5K | |
| 85007 | <1% | 2,723 | $5K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 65 | $5K |
| 82784 | <1% | 479 | $5K | |
| 82248 | <1% | 945 | $5K | |
| 87799 | <1% | 68 | $5K | |
| 99441 | <1% | 419 | $4K | |
| 88307 | <1% | 46 | $4K | |
| 94060 | <1% | 124 | $4K | |
| 86780 | <1% | 891 | $4K | |
| 87075 | <1% | 318 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,938 | $4K |
| 73562 | <1% | 19 | $4K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 979 | $4K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 14 | $4K |
| 84436 | <1% | 161 | $4K | |
| 77061 | <1% | 224 | $4K | |
| 86706 | <1% | 465 | $3K | |
| 94010 | <1% | 124 | $3K | |
| 92587 | <1% | 96 | $3K | |
| 90723 | <1% | 1,873 | $3K | |
| 81243 | <1% | 14 | $3K | |
| 77417 | <1% | 25 | $3K | |
| 81329 | <1% | 14 | $3K | |
| 90651 | <1% | 117 | $3K | |
| 87641 | <1% | 140 | $3K | |
| 81513 | <1% | 46 | $3K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 125 | $3K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 77 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 34 | $3K |
| 74022 | <1% | 58 | $3K | |
| 51798 | <1% | 428 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 785 | $2K |
| 82947 | <1% | 326 | $2K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 154 | $2K |
| 80164 | <1% | 51 | $2K | |
| 99173 | <1% | 1,521 | $2K | |
| 87147 | <1% | 902 | $2K | |
| 95957 | <1% | 43 | $2K | |
| 73080 | <1% | 82 | $2K | |
| 90671 | <1% | 177 | $2K | |
| 83520 | <1% | 37 | $2K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 15 | $2K |
| 90633 | <1% | 567 | $2K | |
| 83516 | <1% | 27 | $2K | |
| 70491 | <1% | 13 | $2K | |
| 86769 | <1% | 32 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 79 | $2K |
| 71271 | <1% | 25 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 885 | $2K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 234 | $2K |
| 87512 | <1% | 33 | $2K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 406 | $2K |
| 82040 | <1% | 526 | $2K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 188 | $2K |
| 94618 | <1% | 52 | $2K | |
| 93246 | <1% | 48 | $2K | |
| 52281 | <1% | 16 | $1K | |
| 36430 | <1% | 41 | $1K | |
| 87015 | <1% | 60 | $1K | |
| 96417 | <1% | 171 | $1K | |
| 51728 | <1% | 13 | $1K | |
| 97113 | <1% | 45 | $1K | |
| 72141 | <1% | 23 | $1K | |
| 97802 | <1% | 28 | $1K | |
| 90680 | <1% | 1,418 | $1K | |
| 80069 | <1% | 151 | $1K | |
| 90656 | <1% | 338 | $1K | |
| 96368 | <1% | 30 | $1K | |
| 82803 | <1% | 255 | $1K | |
| 83883 | <1% | 17 | $1K | |
| 93242 | <1% | 29 | $1K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 82 | $1K |
| 72072 | <1% | 12 | $1K | |
| 86364 | <1% | 92 | $1K | |
| 87420 | <1% | 134 | $959.79 | |
| 99218 | <1% | 109 | $879.00 | |
| 86704 | <1% | 182 | $878.37 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 465 | $807.60 |
| 93325 | <1% | 35 | $743.93 | |
| 99219 | <1% | 31 | $741.97 | |
| 90734 | <1% | 103 | $718.30 | |
| 81002 | <1% | 464 | $694.85 | |
| 51797 | <1% | 13 | $688.85 | |
| 86430 | <1% | 16 | $685.11 | |
| 84402 | <1% | 32 | $667.86 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 610 | $643.24 |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 19 | $583.53 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 491 | $576.67 |
| 99385 | <1% | 12 | $536.40 | |
| 96402 | <1% | 26 | $516.65 | |
| 99381 | <1% | 14 | $490.51 | |
| 94664 | <1% | 140 | $486.70 | |
| 77062 | <1% | 32 | $481.30 | |
| Q3014 | Telehealth originating site facility fee | <1% | 76 | $472.46 |
| 82077 | <1% | 969 | $458.78 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 297 | $455.78 |
| 76813 | <1% | 12 | $453.26 | |
| 77080 | <1% | 13 | $439.11 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 30 | $435.53 |
| 99221 | <1% | 35 | $387.76 | |
| 92610 | <1% | 17 | $372.86 | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 45 | $363.87 |
| 80329 | <1% | 193 | $363.37 | |
| 90474 | <1% | 275 | $310.63 | |
| 86920 | <1% | 57 | $295.98 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 156 | $278.29 |
| 86778 | <1% | 56 | $275.55 | |
| 96523 | <1% | 30 | $245.67 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 489 | $241.54 |
| 80320 | <1% | 441 | $229.06 | |
| 87807 | <1% | 21 | $224.84 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 259 | $210.04 |
| 86431 | <1% | 53 | $205.61 | |
| 82140 | <1% | 39 | $200.62 | |
| 83521 | <1% | 47 | $200.31 | |
| 72040 | <1% | 14 | $198.61 | |
| 99442 | <1% | 12 | $194.38 | |
| 80055 | <1% | 17 | $194.08 | |
| 90696 | <1% | 27 | $193.80 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 458 | $192.86 |
| 85045 | <1% | 156 | $189.73 | |
| 82397 | <1% | 15 | $186.95 | |
| 90707 | <1% | 53 | $183.20 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 237 | $166.77 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 323 | $159.91 |
| 84163 | <1% | 12 | $156.34 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 462 | $156.00 |
| 90716 | <1% | 39 | $136.70 | |
| 73552 | <1% | 12 | $135.49 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 484 | $134.31 |
| 72050 | <1% | 17 | $132.93 | |
| 82009 | <1% | 16 | $125.10 | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 107 | $120.82 |
| 74230 | <1% | 20 | $119.16 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 146 | $105.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 465 | $104.94 |
| 84165 | <1% | 47 | $100.27 | |
| 86308 | <1% | 36 | $94.78 | |
| 90700 | <1% | 17 | $86.45 | |
| 90620 | <1% | 23 | $81.90 | |
| 90710 | <1% | 39 | $76.90 | |
| 90658 | <1% | 14 | $72.74 | |
| 51741 | <1% | 13 | $65.66 | |
| 82247 | <1% | 18 | $64.41 | |
| 87210 | <1% | 85 | $57.98 | |
| 92611 | <1% | 17 | $57.86 | |
| 73090 | <1% | 29 | $46.26 | |
| 84520 | <1% | 46 | $45.93 | |
| 90473 | <1% | 22 | $41.63 | |
| J1815 | Injection, insulin, per 5 units | <1% | 32 | $40.35 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 355 | $35.61 |
| 73060 | <1% | 16 | $33.14 | |
| 80349 | <1% | 26 | $31.68 | |
| 84145 | <1% | 21 | $30.02 | |
| 90694 | <1% | 30 | $29.17 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 133 | $25.57 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 73 | $24.87 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 134 | $20.96 |
| 86923 | <1% | 18 | $19.30 | |
| 96380 | <1% | 14 | $16.69 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 15 | $11.12 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 481 | $8.94 |
| Q2039 | Influenza virus vaccine, not otherwise specified | <1% | 14 | $8.11 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 97 | $6.24 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 176 | $5.45 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 16 | $5.15 |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | <1% | 41 | $4.34 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 42 | $4.34 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 24 | $3.63 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 69 | $2.93 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 617 | $2.40 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 51 | $1.00 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 71 | $0.14 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 169 | $0.04 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 73 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 18 | $0.00 |
| 3074F | 0% | 13 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 73 | $0.00 |
| 93356 | 0% | 13 | $0.00 | |
| 76376 | 0% | 46 | $0.00 | |
| 90461 | 0% | 49 | $0.00 | |
| 3078F | 0% | 13 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 18 | $0.00 |
| 00811 | 0% | 12 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRIESMEYER, JANICE (CREDENTIALING COORDINATOR)
| Provider | Location | Paid |
|---|---|---|
| Wheeling Hospital Ambulatory Surgery Center LLC | Bridgeport, OH | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.